Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;74(5):2410-2423.
doi: 10.1002/hep.31845. Epub 2021 Aug 25.

Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

Affiliations

Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

Tracey G Simon et al. Hepatology. 2021 Nov.

Abstract

Background and aims: Recent studies link NAFLD to an increased incidence of HCC and extrahepatic cancers. However, earlier studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity.

Approach and results: We conducted a population-based cohort study of all adults with histologically defined NAFLD in Sweden from 1966 to 2016 (N = 8,892). NAFLD was defined from prospectively recorded liver histopathology submitted to all 28 Swedish pathology departments and categorized as simple steatosis, nonfibrotic NASH, noncirrhotic fibrosis, and cirrhosis. NAFLD patients were individually matched to ≤5 general population controls without NAFLD by age, sex, calendar year, and county (N = 39,907). Using Cox proportional hazards modeling, we calculated multivariable adjusted HRs (aHRs) and 95% CIs. Over a median of 13.8 years, we documented 1,691 incident cancers among NAFLD patients and 6,733 among controls. Compared with controls, NAFLD patients had significantly increased overall cancer incidence (10.9 vs. 13.8 per 1,000 person-years [PYs]; difference = 2.9 per 1,000 PYs; aHR, 1.27 [95% CI, 1.18-1.36]), driven primarily by HCC (difference = 1.1 per 1,000 PYs; aHR, 17.08 [95% CI, 11.56-25.25]). HCC incidence rates increased monotonically across categories of simple steatosis, nonfibrotic NASH, noncirrhotic fibrosis, and cirrhosis (0.8 per 1,000 PYs, 1.2 per 1,000 PYs, 2.3 per 1,000 PYs, and 6.2 per 1,000 PYs, respectively; Ptrend < 0.01) and were further amplified by diabetes (1.2 per 1,000 PYs, 2.9 per 1,000 PYs, 7.2 per 1,000 PYs, and 15.7 per 1,000 PYs, respectively). In contrast, NAFLD was associated with modestly increased rates of pancreatic cancer, kidney/bladder cancer, and melanoma (differences = 0.2 per 1,000 PYs, 0.1 per 1,000 PYs, and 0.2 per 1,000 PYs, respectively), but no other cancers.

Conclusions: Compared with controls, patients with biopsy-proven NAFLD had significantly increased cancer incidence, attributable primarily to HCC, whereas the contribution of extrahepatic cancers was modest. Although HCC risk was highest with cirrhosis, substantial excess risk was also found with noncirrhotic fibrosis and comorbid diabetes.

PubMed Disclaimer

Conflict of interest statement

Dr. Ludvigsson coordinates an unrelated study on behalf of the Swedish Inflammatory Bowel Disease Registry (SWIBREG) that has received funding from Janssen Corporation. Dr. Simon’s institution has received grants from Amgen, and she has served as a consultant to Aetion for work unrelated to this manuscript. Dr. Hagström’s institution has received research grants from AstraZeneca, Intercept, and Gilead, and he has served on the advisory board for Bristol Myers Squibb and Gilead.

Figures

FIG. 1.
FIG. 1.
Cumulative incidence of overall cancer according to the prevalence and histological severity of NAFLD. NAFLD histological severity was defined in four categories: simple steatosis, NASH without fibrosis, noncirrhotic fibrosis, and cirrhosis. (For details, see Supporting Methods.) P values for the absolute incidence RDs for overall cancer between population comparators versus simple steatosis, NASH without fibrosis, noncirrhotic fibrosis, and cirrhosis were all <0.001. P values were approximated using the normal distribution. Abbreviations: NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; RDs, rate differences; ref., referent.
FIG. 2.
FIG. 2.
Cumulative incidence of HCC according to the presence and histological severity of NAFLD. NAFLD histological severity was defined in four categories: simple steatosis, NASH without fibrosis, noncirrhotic fibrosis, and cirrhosis. (For details, see Supporting Methods.) P values for the absolute incidence RDs for incident HCC between population comparators versus simple fibrosis, noncirrhotic fibrosis, and cirrhosis were all <0.001. P values were approximated using the normal distribution. Abbreviation: HCC, hepatocellular carcinoma.

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. - PubMed
    1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863–869. - PubMed
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285. - PubMed
    1. Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020;158:611–1625.e12. - PubMed
    1. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557–1565. - PMC - PubMed

Publication types

MeSH terms